Get your full text copy in PDF
Uwe Fuchs, Sarah Klein, Armin Zittermann, Stephan M. Ensminger, Uwe Schulz, Jan F. Gummert
(Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Bad Oeynhausen, Germany)
Ann Transplant 2014; 19:300-304
Heart transplant recipients are at increased risk of developing malignant neoplasms. Administration of the calcineurin inhibitors cyclosporine A (CSA) or tacrolimus (TAC) may contribute to this risk.
Material and Methods: We compared tumor incidence in heart transplant recipients receiving either CSA (n=25) or TAC (n=120) as maintenance immunosuppressive therapy. Exclusion criteria were therapy with mammalian target of rapamycin-inhibitors, death within the first postoperative year, re-transplantation, and age less than 18 years.
Results: The 2 study groups were comparable with respect to sex, primary and concomitant diagnoses, and mean follow-up (60.7±19.3 months in the CSA group vs. 59.8±18.1 months in the TAC group; P=0.81). The CSA group was, however, significantly older compared with the TAC group (58.8±11.4 years vs. 49.1±13.0 years, P=0.001), as was the donor age of the CSA group (43.2±11.2 years vs. 37.0±11.7 years, P=0.02). In the CSA group, 5 patients (20%) developed malignant neoplasms compared with 10 patients (8.3%) in the TAC group (P=0.14). Covariate-adjusted 5-year tumor-free survival was comparable between groups (relative risk for the CSA group =1.162 [95% CI: 0.378–3.572; P=0.794]). Moreover, covariate-adjusted 5-year overall survival did not differ between the 2 groups (relative risk for the CSA group =1.95 [95% CI: 0.53–7.19; P=0.36). The incidence of infection, acute rejection, graft vasculopathy, renal failure, and neurological complications was also comparable between the 2 groups.
Conclusions: Our data indicate that tumor incidence does not significantly differ in patients receiving CSA or TAC as maintenance therapy.
Keywords: Neoplasms, Second Primary, Tacrolimus, Cyclosporine A, Immunosuppression, calcineurin-inhibitors, Heart Transplantation